2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1259

Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series
Abstract Number: 1260

The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis
Abstract Number: 1261

The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis
Abstract Number: 1262

Clinical Features of Elderly-onset Adult Still’s Disease
Abstract Number: 1263

The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center
Abstract Number: 1264

Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients
Abstract Number: 1265

Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients
Abstract Number: 1266

AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab
Abstract Number: 1267

Epidemology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study
Abstract Number: 1268

Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?
Abstract Number: 1269

Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Abstract Number: 1270

Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Abstract Number: 1271

Adult-Onset Still’s Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment
Abstract Number: 1272

Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study
Abstract Number: 1273

Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].